Clinical trials: Spasticity
Post-Stroke Spasticity, Cerebrovascular Accident
Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
This is a study to confirm the superior efficacy of GSK1358820 over placebo in patients with equinus deformity associated with post-stroke lower limb spasticity using the Modified Ashworth Scale (MAS) ankle score.
- Trial name
- NCT00460655
- Testing
- GSK1358820
- Where
- 20 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Cerebrovascular Accident, Muscle Spasticity
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.
- Trial name
- NCT00216411
- Testing
- Botulinum toxin type A
- Where
- 6 sites in Australia
- Volunteers
- 96 people
- Sponsor
- Ipsen
Spasticity
Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA
The aim of the study is to describe the long-term use of abobotulinumtoxinA (Dysport®) in adult subjects affected with upper limb spasticity (ULS) +/- lower limb spasticity (LLS) who received treatment with Dysport® for a minimum…
- Trial name
- RETURN (NCT04446702)
- Where
- Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ipsen
Spasticity
MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
This study is a randomized, double blind, multi-center, active drug controlled, phase III clinical trial to compare the efficacy and safety of MEDITOXIN® versus BOTOX® in treatment of post stroke upper limb(wrist, finger, thumb)…
- Trial name
- NCT01313767
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Medy-Tox
Spinal Cord Injury, Muscle Spasticity
Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs.
- Trial name
- NCT01683838
- Testing
- Fampridine-SR
- Where
- 30 sites in United States, Canada
- Volunteers
- 204 people
- Sponsor
- Acorda Therapeutics
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/adolescents (age 2-17 years) long-term with increased muscle…
- Trial name
- NCT01905683
- Testing
- IncobotulinumtoxinA (16-20 Units per kg body weight)
- Where
- 43 sites in Austria, Czechia and 10 more
- Volunteers
- 370 people
- Sponsor
- Merz Pharmaceuticals GmbH
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS)…
- Trial name
- NCT01844232
- Testing
- arbaclofen
- Where
- 35 sites in United States, Russia and 1 more
- Volunteers
- 150 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Spasticity in Participants With Multiple Sclerosis
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale…
- Trial name
- RELEASE MSS1 (NCT04657666)
- Testing
- Nabiximols
- Where
- 16 sites in Czechia, Poland
- Volunteers
- 68 people
- Sponsor
- Jazz Pharmaceuticals
Cerebral Palsy, Muscle Spasticity
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
The purpose of this research study was to determine the long term safety and efficacy of repeated treatments with Dysport® used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to…
- Conditions
- Cerebral Palsy, Muscle Spasticity, Children
- Trial name
- NCT01251380
- Testing
- Botulinum toxin type A
- Where
- 27 sites in United States, Chile and 4 more
- Volunteers
- 216 people
- Sponsor
- Ipsen
AMN, AMN Gene Mutation
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
The course of AMN-related disabilities over time is poorly or incompletely understood due to a limited number of patients and lack of treatments.
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- CYGNET (NCT05008874)
- Testing
- Natural History Observation
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- SwanBio Therapeutics, Inc.
Muscle Spasticity
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following…
- Trial name
- NCT00358293
- Testing
- Tizanidine (sublingual or oral)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Teva GTC
Muscle Spasticity
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
This is a prospective, non-interventional, observational study to collect data on the use of botulinum toxin Type A in a routine setting in patients with upper limb adult spasticity.
- Trial name
- NCT01387074
- Testing
- botulinum toxin Type A
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergan
Post Stroke Arm Spasticity
Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke
The objective of this non-interventional study is to evaluate clinical effectiveness and cost effectiveness of Dysport within the reimbursement scheme called "drug programme" funded by Polish National Health Fund (NHF) for…
- Trial name
- PSAS REGISTRY (NCT02444494)
- Where
- 6 sites in Poland
- Volunteers
- 108 people
- Sponsor
- Ipsen
Spasticity
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total…
- Trial name
- LANTIMA (NCT04752774)
- Testing
- Corabotase, Dysport
- Where
- 81 sites in United States, Austria and 12 more
- Volunteers
- 240 people
- Sponsor
- Ipsen
Muscle Spasticity
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury
- Trial name
- NCT00557973
- Testing
- XP19986 SR1, 10 mg BID, XP19986 SR1, 20 mg BID, XP19986 SR1, 30 mg BID
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- XenoPort, Inc.
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Post-stroke Upper Limb Spasticity
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin.
- Trial name
- NCT00432666
- Testing
- IncobotulinumtoxinA (Xeomin)
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 148 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cerebral Palsy
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
The purpose of the study is to compare the effectiveness of 3 doses of Dysport (5, 10 or 15 Units/Kg/hip) in the management of chronic bilateral hip pain due to cerebral palsy in children/young people.
- Trial name
- NCT00455637
- Testing
- Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Ipsen